Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation.
Hepatol Int
; 14(4): 432-436, 2020 Jul.
Article
in English
| MEDLINE | ID: covidwho-46871
ABSTRACT
Annually, around 850 liver transplantation is performed in Beijing, China. Recently, the new coronavirus pneumonia (COVID-19) caused by 2019 novel coronavirus (2019-nCoV) has affected nearly 200 countries worldwide. 2019-nCov can cause severe lung disease, multiple-organ damage, and significant mortalities. Liver transplant recipients, because of long-term oral immunosuppressant effects, may be more susceptible to 2019-nCoV infection and have a worse prognosis than the general population. It is urgent to set up guidelines for the prevention, diagnosis, and treatment of COVID-19 in liver transplant recipients. In this article, we reviewed the clinical aspects of 2019-nCoV infection, characteristics of liver transplant recipients, immunosuppressant usage, and potential drug interactions to provide recommendations to clinical staff managing liver transplant recipients during the COVID-19 epidemic.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Liver Transplantation
/
Coronavirus Infections
/
Betacoronavirus
/
Liver Diseases
Type of study:
Diagnostic study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Hepatol Int
Year:
2020
Document Type:
Article
Affiliation country:
S12072-020-10043-z
Similar
MEDLINE
...
LILACS
LIS